Chemomab Therapeutics (CMMB) Common Equity (2017 - 2025)

Chemomab Therapeutics (CMMB) has 9 years of Common Equity data on file, last reported at $12.3 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity fell 8.89% year-over-year to $12.3 million; the trailing twelve-month figure through Dec 2025 stood at $12.3 million (down 8.89% YoY), and the FY2025 full-year result was $12.3 million, down 8.89% from the prior year.
• Common Equity for Q4 2025 stood at $12.3 million, down from $13.5 million in the prior quarter.
• Across five years, Common Equity topped out at $68.0 million in Q2 2021 and bottomed at $12.3 million in Q4 2025.
• The 5-year median for Common Equity is $48.2 million (2022), against an average of $42.6 million.
• The widest annual swing landed in 2021, when Common Equity jumped 469.02%; it then sank 53.08% in 2023.
• A 5-year view of Common Equity shows it stood at $61.5 million in 2021, then tumbled by 41.07% to $36.2 million in 2022, then sank by 53.08% to $17.0 million in 2023, then decreased by 20.36% to $13.5 million in 2024, then dropped by 8.89% to $12.3 million in 2025.
• The last three Common Equity figures came in at $12.3 million (Q4 2025), $13.5 million (Q4 2024), and $17.0 million (Q4 2023), per Business Quant data.

Peer Comparison